Iterum Therapeutics Overview

  • Year Founded
  • 2015

Year Founded

  • Status
  • Public

  • Employees
  • 9

Employees

  • Stock Symbol
  • ITRMF

Stock Symbol

Iterum Therapeutics General Information

Description

Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the designated microorganisms, without the presence of known toxicities of some other antibiotics. The company operates in a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 25 North Wall Quay
  • Dublin D01 H104
  • Ireland
+353 (01)
Primary Industry
Pharmaceuticals
Other Industries
Biotechnology
Stock Exchange
OTCM
Corporate Office
  • 25 North Wall Quay
  • Dublin D01 H104
  • Ireland
+353 (01)

Iterum Therapeutics Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Iterum Therapeutics Stock Performance

As of 04-Aug-2026, Iterum Therapeutics’s current market cap is $533.00 with 53.3M shares.

(As of Tuesday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$533.00 53.3M 96.5K -$0.76

Iterum Therapeutics Financials Summary

As of 30-Sep-2025, Iterum Therapeutics has a trailing 12-month revenue of $390K.

In Thousands,
USD
TTM 30-Sep-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023 FY 2022 31-Dec-2022
EV 49,452 56,637 10,169 (23,864)
Revenue 390 0 0 0
EBITDA (23,204) (21,728) (34,580) (39,972)
Net Income (26,961) (24,774) (38,371) (44,434)
Total Assets 32,503 44,595 26,259 66,833
Total Debt 33,735 45,534 18,956 28,466
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Iterum Therapeutics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Iterum Therapeutics‘s full profile, request access.

Request a free trial

Iterum Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an ora
Pharmaceuticals
Dublin, Ireland
9 As of 2024

Boston, MA
 

Carlton, Australia
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Iterum Therapeutics Competitors (105)

One of Iterum Therapeutics’s 105 competitors is Rhythm Pharmaceuticals, a Formerly VC-backed company based in Boston, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Rhythm Pharmaceuticals Formerly VC-backed Boston, MA
Immuron Corporation Carlton, Australia
TheraCryf Formerly VC-backed Nether Alderley, United Kingdom
Nabriva Therapeutics Formerly VC-backed Dublin, Ireland
Achaogen Formerly VC-backed South San Francisco, CA
You’re viewing 5 of 105 competitors. Get the full list »

Iterum Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Iterum Therapeutics Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Iterum Therapeutics‘s full profile, request access.

Request a free trial

Iterum Therapeutics ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Pharmaceuticals

Industry

Rank

Percentile

Biotechnology

Subindustry

Rank

Percentile

To view Iterum Therapeutics’s complete esg history, request access »

Iterum Therapeutics FAQs

  • When was Iterum Therapeutics founded?

    Iterum Therapeutics was founded in 2015.

  • Where is Iterum Therapeutics headquartered?

    Iterum Therapeutics is headquartered in Dublin, Ireland.

  • What is the size of Iterum Therapeutics?

    Iterum Therapeutics has 9 total employees.

  • What industry is Iterum Therapeutics in?

    Iterum Therapeutics’s primary industry is Pharmaceuticals.

  • Is Iterum Therapeutics a private or public company?

    Iterum Therapeutics is a Public company.

  • What is Iterum Therapeutics’s stock symbol?

    The ticker symbol for Iterum Therapeutics is ITRMF.

  • What is the current market cap of Iterum Therapeutics?

    The current market capitalization of Iterum Therapeutics is $533.00.

  • What is Iterum Therapeutics’s current revenue?

    The trailing twelve month revenue for Iterum Therapeutics is $390K.

  • Who are Iterum Therapeutics’s competitors?

    Rhythm Pharmaceuticals, Immuron, TheraCryf, Nabriva Therapeutics, and Achaogen are some of the 105 competitors of Iterum Therapeutics.

  • What is Iterum Therapeutics’s annual earnings per share (EPS)?

    Iterum Therapeutics’s EPS for 12 months was -$0.76.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process